AnaptysBio (NASDAQ:ANAB) PT Lowered to $93.00 at SunTrust Banks

Share on StockTwits

AnaptysBio (NASDAQ:ANAB) had its target price decreased by SunTrust Banks from $125.00 to $93.00 in a research report report published on Monday, The Fly reports. SunTrust Banks currently has a buy rating on the biotechnology company’s stock. SunTrust Banks also issued estimates for AnaptysBio’s FY2020 earnings at ($4.73) EPS.

ANAB has been the subject of a number of other reports. Zacks Investment Research raised shares of AnaptysBio from a sell rating to a buy rating and set a $77.00 target price for the company in a report on Wednesday, March 6th. Credit Suisse Group lowered shares of AnaptysBio from an outperform rating to a neutral rating and dropped their price objective for the stock from $137.00 to $79.00 in a research note on Friday, June 21st. Cantor Fitzgerald reaffirmed a buy rating and set a $140.00 price objective on shares of AnaptysBio in a research note on Wednesday, February 27th. Wedbush reiterated an outperform rating on shares of AnaptysBio in a research report on Friday, March 1st. Finally, Stifel Nicolaus set a $124.00 target price on AnaptysBio and gave the stock a buy rating in a research report on Wednesday, May 8th. Five investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock currently has a consensus rating of Buy and an average target price of $111.25.

ANAB stock opened at $53.76 on Monday. The firm has a fifty day simple moving average of $70.56. AnaptysBio has a fifty-two week low of $52.93 and a fifty-two week high of $110.00. The stock has a market capitalization of $1.45 billion, a price-to-earnings ratio of -21.50 and a beta of 1.98.

AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.82) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.01. Sell-side analysts expect that AnaptysBio will post -3.76 EPS for the current fiscal year.

In other AnaptysBio news, insider Marco Londei sold 10,060 shares of the business’s stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $73.06, for a total value of $734,983.60. Following the completion of the transaction, the insider now directly owns 32,437 shares in the company, valued at $2,369,847.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Hamza Suria sold 22,428 shares of the business’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $73.76, for a total transaction of $1,654,289.28. Following the completion of the transaction, the chief executive officer now owns 31,524 shares of the company’s stock, valued at $2,325,210.24. The disclosure for this sale can be found here. Insiders own 14.00% of the company’s stock.

Institutional investors have recently made changes to their positions in the business. Diag Capital Management LP bought a new position in AnaptysBio in the fourth quarter worth about $95,000. Amundi Pioneer Asset Management Inc. bought a new position in AnaptysBio in the first quarter worth about $110,000. SG Americas Securities LLC bought a new position in AnaptysBio in the fourth quarter worth about $126,000. Bank of America Corp DE raised its holdings in AnaptysBio by 141.2% in the fourth quarter. Bank of America Corp DE now owns 4,397 shares of the biotechnology company’s stock worth $281,000 after purchasing an additional 15,067 shares in the last quarter. Finally, Janney Montgomery Scott LLC bought a new position in AnaptysBio in the first quarter worth about $290,000.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases.

Featured Story: Trading Options- What is a Strangle?

The Fly

Analyst Recommendations for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Red Rock Resorts  Stock Rating Lowered by TheStreet
Red Rock Resorts Stock Rating Lowered by TheStreet
Short Interest in Ardmore Shipping Corp  Declines By 19.5%
Short Interest in Ardmore Shipping Corp Declines By 19.5%
Brokerages Expect Culp, Inc.  to Post $0.15 Earnings Per Share
Brokerages Expect Culp, Inc. to Post $0.15 Earnings Per Share
Bloom Energy  Downgraded by Zacks Investment Research
Bloom Energy Downgraded by Zacks Investment Research
Byline Bancorp  Downgraded by Zacks Investment Research
Byline Bancorp Downgraded by Zacks Investment Research
Athene  Stock Rating Lowered by Zacks Investment Research
Athene Stock Rating Lowered by Zacks Investment Research


 
© 2006-2019 Zolmax.